Anti-bacterial applications of poly-N-acetylglucosamine nanofibers

Inventors

Vournakis, John N. • Finkielsztein, Sergio

Assignees

Marine Polymer Technologies Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10206938-B2

Patent

Publication Date

2019-02-19

Expiration Date


Abstract

Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.

Core Innovation

The disclosure describes shortened poly-β-1→4-N-acetylglucosamine nanofibers (sNAG nanofibers) for topical use in treating acne and treating or preventing dermatitis caused by or associated with a bacterial infection in a human subject. The sNAG nanofibers comprise 70% or more than 70% of N-acetylglucosamine monosaccharides and are defined by a nanofiber length distribution criterion or a molecular weight criterion together with a foreign body reaction limitation.

The antibacterial effect is described as indirect, because the sNAG nanofibers do not have a substantial direct effect on Staphylococcus aureus growth or survival in vitro. Instead, the disclosure links the effect to innate immune pathway activation, including Akt1/Ets1 signaling, phospho-Akt and Ets1, defensin induction, and upregulation of Toll-like receptors.

The disclosed results include reduced Staphylococcus aureus wound bacterial load in vivo and preclinical biocompatibility and irritation testing indicating non-toxicity, weak allergen potential, and low irritation. The disclosure also states that treatment of a wound with the sNAG nanofibers does not elicit a detectable foreign body reaction in 14 days after treatment.

Claims Coverage

The consolidated content provides two independent claims. Both claims center on topical application of defined sNAG nanofibers to the skin of a human subject, with monosaccharide content and fiber size or molecular-weight limits, a foreign body reaction limitation, and a requirement that the sNAG nanofibers do not have an effect, or substantially have no effect, on Staphylococcus aureus growth or survival in vitro.

Topical acne treatment using defined sNAG nanofibers

A method for treating acne in a human subject comprising topically applying a composition comprising shortened poly-β-1→4-N-acetylglucosamine fibers (sNAG nanofibers) to the skin of a human subject in need thereof, wherein the sNAG nanofibers comprise 70% or more than 70% N-acetylglucosamine monosaccharides and wherein more than 50% of the sNAG nanofibers are between 1 to 15 μm in length, or the sNAG nanofibers have a molecular weight between about 20 kDa to 75 kDa and treatment of a wound with the sNAG nanofibers does not elicit a detectable foreign body reaction in 14 days after treatment, and wherein the sNAG nanofibers do not have an effect, or substantially have no effect, on bacterial growth or survival of Staphylococcus aureus bacterial cultures in vitro.

Topical treatment or prevention of dermatitis associated with bacterial infection using defined sNAG nanofibers

A method for treating or preventing dermatitis caused by or associated with a bacterial infection in a human subject comprising topically applying a composition comprising shortened poly-β-1→4-N-acetylglucosamine fibers (sNAG nanofibers) to the skin of a human subject in need thereof, wherein the sNAG nanofibers comprise 70% or more than 70% N-acetylglucosamine monosaccharides and wherein more than 50% of the sNAG nanofibers are between 1 to 15 μm in length, or the sNAG nanofibers have a molecular weight between about 20 kDa to 75 kDa and treatment of a wound with the sNAG nanofibers does not elicit a detectable foreign body reaction in 14 days after treatment, and wherein the sNAG nanofibers do not have an effect, or substantially have no effect, on bacterial growth or survival of Staphylococcus aureus bacterial cultures in vitro.

Across the independent claims, the coverage centers on topical treatment of acne or dermatitis associated with bacterial infection using sNAG nanofibers with defined monosaccharide content and length or molecular-weight criteria, combined with a no detectable foreign body reaction limitation and a non-biocide criterion against Staphylococcus aureus in vitro.

Stated Advantages

Provides an antibacterial effect without substantial direct inhibition of Staphylococcus aureus growth or survival in vitro.

Stimulates innate immune pathways, including defensin induction and Toll-like receptor upregulation mediated by Akt1/Ets1 signaling.

Reduces Staphylococcus aureus wound bacterial load in vivo.

Does not elicit a detectable foreign body reaction in 14 days after treatment under the molecular weight criterion.

Preclinical biocompatibility and irritation testing indicates non-toxicity, weak allergen potential, and low irritation.

Documented Applications

Topical application to the skin for treating acne in a human subject.

Topical treatment or prevention of dermatitis caused by or associated with a bacterial infection on human skin.

Cutaneous wound healing contexts in which sNAG promotes defensin expression and reduces wound bacterial load in vivo.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.